Seagen Drug Patent Portfolio
Seagen owns 1 orange book drug protected by 8 US patents Given below is the list of Seagen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11207324 | Treatment of HER2 positive cancers | 27 Apr, 2038 | Active |
| US11666572 | Treatment of HER2 positive cancers | 27 Apr, 2038 | Active |
| US12048698 | Treatment of HER2 positive cancers | 27 Apr, 2038 | Active |
| US11504370 | Treatment of brain cancer | 25 Mar, 2033 | Active |
| US9457093 | Solid dispersions of a ERB2 (HER2) inhibitor | 12 Oct, 2032 | Active |
| US8648087 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | 12 Apr, 2031 | Active |
| US9693989 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | 09 May, 2027 | Active |
| US7452895 | Quinazoline analogs as receptor tyrosine kinase inhibitors | 16 Nov, 2024 | Expired |
Latest Legal Activities on Seagen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Seagen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 29 May, 2024 | US9693989 |
| Mail Pre-Exam Notice | 29 May, 2024 | US9693989 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 29 May, 2024 | US9693989 |
| Patent eCofC Notification | 16 Apr, 2024 | US11666572 |
|
Email Notification
Critical
| 16 Apr, 2024 | US11666572 |
| Mail Patent eCofC Notification | 16 Apr, 2024 | US11666572 |
| Recordation of Patent eCertificate of Correction | 16 Apr, 2024 | US11666572 |
| Post Issue Communication - Certificate of Correction | 29 Mar, 2024 | US11666572 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Mar, 2024 | US9457093 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9457093 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9693989 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8648087 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US7452895 |
| transaction for FDA Determination of Regulatory Review Period | 29 Nov, 2023 | US9693989 |
| transaction for FDA Determination of Regulatory Review Period | 29 Nov, 2023 | US7452895 |
Seagen Drug Patents' Oppositions Filed in EPO
Seagen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 01, 2021, by Sandoz Ag. This opposition was filed on patent number EP18162971A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP18162971A | Sep, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP18162971A | Sep, 2021 | Sandoz AG | Granted and Under Opposition |
Seagen's Family Patents
Seagen Drug List
Given below is the complete list of Seagen's drugs and the patents protecting them.
1. Tukysa
Tukysa is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11207324 | Treatment of HER2 positive cancers |
27 Apr, 2038
(13 years from now)
| Active |
| US11666572 | Treatment of HER2 positive cancers |
27 Apr, 2038
(13 years from now)
| Active |
| US12048698 | Treatment of HER2 positive cancers |
27 Apr, 2038
(13 years from now)
| Active |
| US11504370 | Treatment of brain cancer |
25 Mar, 2033
(8 years from now)
| Active |
| US9457093 | Solid dispersions of a ERB2 (HER2) inhibitor |
12 Oct, 2032
(7 years from now)
| Active |
| US8648087 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
12 Apr, 2031
(6 years from now)
| Active |
| US9693989 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
09 May, 2027
(2 years from now)
| Active |
| US7452895 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
16 Nov, 2024
(a month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tukysa's drug page